Bayer Healthcare LLC

CIK: 0001231517

Transaction Breakdown

Open Market Buys (P)2 (66.7%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)0 (0.0%)

Compensation grants

Other (G, F, J, C, D, …)1 (33.3%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

SNTI

Senti Biosciences, Inc.

10% Owner

Discretionary Trading P&L

Holdings

Transaction History (3 total)

SNTI
Senti Biosciences, Inc.
Mar 10, 2025
Conversion(C)
Direct
2.2M shares-
SNTI
Senti Biosciences, Inc.
Dec 9, 2024
Purchase(P)
Series A Convertible Preferred Stock
Direct
2.2K shares-
SNTI
Senti Biosciences, Inc.
Dec 9, 2024
Purchase(P)
Warrant
Direct
3.3M shares-

		Type	Shares	Price		Ownership
Mar 10, 2025	SNTI Senti Biosciences, Inc.	Conversion(C)	2,222,000	-	-	Direct
Dec 9, 2024	SNTI Senti Biosciences, Inc.	Purchase(P) Series A Convertible Preferred Stock	2,222	-	-	Direct
Dec 9, 2024	SNTI Senti Biosciences, Inc.	Purchase(P) Warrant	3,333,000	-	-	Direct

1-3 of 3 transactions

About BAYER HEALTHCARE LLC

BAYER HEALTHCARE LLC (SEC CIK 0001231517) files insider reports with the SEC as 10% Owner of Senti Biosciences, Inc. (SNTI).

Signal8 holds 2 ownership filings by BAYER HEALTHCARE LLC, all Form 4s, filed between Dec 11, 2024 and Mar 12, 2025. Those filings report 3 transactions, from Dec 9, 2024 to Mar 10, 2025. Signal8's Form 4 history starts in Sep 2024.

The business address on BAYER HEALTHCARE LLC's filings is in WHIPPANY, NJ.

Recent filings by BAYER HEALTHCARE LLC

Mar 10, 2025: Conversion of SNTI shares (Form 4, code C).
Dec 9, 2024: Open-market purchases of SNTI derivative securities (2 lines, Form 4, code P).

Other insiders filing for Senti Biosciences, Inc. (SNTI)

Rajangam Kanya, Pres. & Chief Med. & Dev. Off.
Lu Timothy K, CEO
Baum Bryan Daniel, Director
Collins James J., Director
Hsiung Feng, Director
Schulz Fran, Director

How to read Form 4 transaction codes